Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: Pathogenesis, prophylaxis, and antiviral therapy
- 1 January 2011
- Vol. 409 (2) , 328-337
- https://doi.org/10.1016/j.virol.2010.10.021
Abstract
No abstract availableKeywords
Funding Information
- NIAID (NOI-AI-15436, 25XS065)
This publication has 59 references indexed in Scilit:
- Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulationBlood, 2010
- Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient miceProceedings of the National Academy of Sciences, 2009
- Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapiesVirology, 2008
- Acyclic nucleoside phosphonates: a key class of antiviral drugsNature Reviews Drug Discovery, 2005
- Genetically Engineered Vesicular Stomatitis Virus in Gene Therapy: Application for Treatment of Malignant DiseaseJournal of Virology, 2002
- Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukinsGene Therapy, 1998
- Infertility in Mice Induced by a Recombinant Ectromelia Virus Expressing Mouse Zona Pellucida Glycoprotein 31Biology of Reproduction, 1998
- A Murine Interleukin-4 Antagonistic Mutant Protein Completely Inhibits Interleukin-4-induced Cell Proliferation, Differentiation, and Signal TransductionJournal of Biological Chemistry, 1997
- Structure of vaccinia virus early promotersJournal of Molecular Biology, 1989
- Association of non-viral proteins with recombinant vaccinia virus virionsArchiv für die gesamte Virusforschung, 1987